Induction of antigen specific immunnologic tolerance
    2.
    发明授权
    Induction of antigen specific immunnologic tolerance 有权
    诱导抗原特异性免疫耐受

    公开(公告)号:US07883707B2

    公开(公告)日:2011-02-08

    申请号:US12412986

    申请日:2009-03-27

    IPC分类号: A61K39/385

    摘要: Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

    摘要翻译: 通过与免疫抑制方案组合施用耐受性,在哺乳动物宿主中诱导抗原特异性免疫耐受性。 所述方法任选地包括前述调节期,其中在不存在耐受性的情况下施用免疫抑制剂。 在耐受方案之后,宿主从抑制剂中排出,但能够对存在于耐受性上的免疫原性表位保持特异性的免疫耐受性。 最佳地,耐受性将具有高吸收性质,其允许在多种耐受细胞类型中以低浓度体内摄取。

    Induction of antigen specific immunologic tolerance
    3.
    发明授权
    Induction of antigen specific immunologic tolerance 失效
    诱导抗原特异性免疫耐受

    公开(公告)号:US07485314B2

    公开(公告)日:2009-02-03

    申请号:US10141668

    申请日:2002-05-06

    IPC分类号: A61K45/00

    摘要: Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

    摘要翻译: 通过与免疫抑制方案组合施用耐受性,在哺乳动物宿主中诱导抗原特异性免疫耐受性。 所述方法任选地包括前述调节期,其中在不存在耐受性的情况下施用免疫抑制剂。 在耐受方案之后,宿主从抑制剂中排出,但能够对存在于耐受性上的免疫原性表位保持特异性的免疫耐受性。 最佳地,耐受性将具有高吸收性质,其允许在多种耐受细胞类型中以低浓度体内摄取。